SEARCH

SEARCH BY CITATION

References

  • 1
    Eastwood D, Bird C, Dilger P, Hockley J, Findlay L, Poole S, Thorpe S, Thorpe R, Wadhwa M, Stebbings R. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br J Clin Pharmacol 2013; 76: 299315.
  • 2
    Tranter E, Peters G, Boyce M, Warrington S. Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe? Br J Clin Pharmacol 2013; 76: 164172.
  • 3
    Smethurst D. A pharmacologic perspective on newly emerging T-cell manipulation technologies. Br J Clin Pharmacol 2013; 76: 173187.
  • 4
    Ferbas J, Belouski S, Horner M, Kaliyaperumal A, Chen L, Boyce M, Colaco B, McHugh N, Quick V, Nicholl R, Siu G, Chung J. A novel assay to measure B cell responses to keyhole limpet hemocyanin vaccination in healthy persons and subjects with systemic lupus erythematosus. Br J Clin Pharmacol 2013; 76: 188202.
  • 5
    Jones D, McBlane J, McNaughton G, Rajakumaraswamy N, Wydenbach K. A regulatory perspective of clinical trial applications for biological products with particular emphasis on advanced therapy medicinal products. Br J Clin Pharmacol 2013; 76: 203209.
  • 6
    Oxford J. Volunteer virus challenge studies in quarantine may speed the development of a universal influenza vaccine. Br J Clin Pharmacol 2013; 76: 210216.
  • 7
    Chtarto A, Bockstael O, Tshibangu T, Dewitte O, Levivier M, Tenenbaum L. A next step in adeno-associated virus (AAV)-mediated gene therapy for neurological diseases: regulation and targeting. Br J Clin Pharmacol 2013; 76: 217232.
  • 8
    Lee C, Cragg M, Glennie M, Johnson P. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol 2013; 76: 233247.
  • 9
    Lambert J. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 2013; 76: 248262.
  • 10
    Böni-Schnetzler M, Donath MY. How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes. Br J Clin Pharmacol 2013; 76: 263268.
  • 11
    Crooke S, Geary R. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol 2013; 76: 269276.
  • 12
    Holgate S. Stratified approaches to the diagnosis and treatment of asthma. Br J Clin Pharmacol 2013; 76: 277291.
  • 13
    Gould D. Gene doping: gene delivery for Olympic victory. Br J Clin Pharmacol 2013; 76: 292298.